ICYMI: Inspire Announces $200 Million Stock Buyback

Inspire is a medical technology company focused on the development and commercialization of innovative, minimally invasive solutions for patients with obstructive sleep apnea. Inspire’s proprietary Inspire therapy is the first and only FDA, EU MDR, and PDMA-approved neuro-stimulation technology that provides a safe and effective treatment for moderate to severe obstructive sleep apnea.
The company last week cut its revenue guidance for the full year, saying the US commercial launch for Inspire V is going slower than expected. On Monday, however, it announced a $200 million stock buyback plan, which representing 8.5% of the company's current market value, data compiled by Bloomberg show.

Tim Herbert, Inspire's Founder, Chairman, President and CEO discusses the reasons for the repurchase program and the health of the company overall. Tim speaks with Tim Stenovec and Carol Massar on Bloomberg Businessweek Daily.

See omnystudio.com/listener for privacy information.